Abstract:Abstract An effective anti-tumor response requires activation of both CD4 helper T cells (through MHC-II) and CD8 cytotoxic T cells (through MHC-I). Activation of tumor-specific T cells depends on tumor antigen presentation by DCs. However, it is known that the tumor microenvironment largely suppresses immune responses. The focus of our study is to characterize the functional status of DCs in tumor-draining lymph nodes (TDLN) and to identify the mechanisms that lead to defective tumor antigen presentation. We transplanted tumors into the flank of mice and analyzed DCs from TDLN and contralateral non-draining lymph nodes (NDLN). Cross-presentation of OVA to CD8 T cells was not suppressed in TDLN either in vivo or ex vivo. However, both in vivo and ex vivo CD4 T cell activation by DCs from TDLNs was defective. Subset analysis revealed that both migratory and resident DCs in TDLN show a less mature phenotype as compared to their counterparts isolated from NDLN. Functional assays revealed defects in antigen uptake by DCs from TDLN. Interestingly, DCs in TDLN also showed poor removal of the Invariant-chain CLIP peptide from the MHC-II peptide binding groove. This is likely to be due to a functional defect of the peptide-editor H2-M. Using Invariant-chain mutant mice and H2-M knock-out mice we confirmed that defective peptide exchange from MHC-II molecules hampered the anti-tumor responses and lead to enhanced tumor growth. These features of DC function, supported by RNA-Seq analysis, contribute to defective antigen presentation to CD4 T cells and may explain the dysfunction of DCs in tumor-bearing mice. Further analysis could allow us to “correct” these DC defects, thereby allowing CD4 T cell priming to provide the necessary help for antitumor CD8 T cells.

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Impaired function of dendritic cells within the tumor microenvironment

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Dendritic cell biology and its role in tumor immunotherapy

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

The role of dendritic cells in cancer immunity and therapeutic strategies

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Dendritic cells dysfunction in tumor-draining lymph nodes

Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton.

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer

Metabolism of Dendritic Cells in Tumor Microenvironment: for Immunotherapy

Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses

Dendritic cell subsets and implications for cancer immunotherapy

Dendritic Cells in Shaping Anti-Tumor T Cell Response

Immunotherapy of targeting MDSCs in tumor microenvironment

Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy

Dysfunction of Dendritic Cells in Tumor-Draining Lymph Nodes

Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target

Think global but act local: Tuning the dendritic cell response in cancer